The core of genes shared by all panels for SNVs (BRAF, CREBBP, CRLF2, EZH2, FLT3, IL7R, JAK1, JAK2, JAK3, KRAS, NF1, NRAS, PAX5, and PTPN11) covered mainly those genes involved in new classification subtypes (such as Ph-like or BCR-ABL1-like, and PAX5 alterations subtypes), which in turn represent new therapeutic targets involved in deregulated cell pathways in ALL [11,12,13,14]. This evidence concerns the gene PTPN11 and acute lymphoblastic leukemia.